Prostate cancer : new horizons in research and treatment /

Uloženo v:
Podrobná bibliografie
Další autoři: Cher, Michael L. (Editor), Raz, Avraham (Editor), Honn, Kenneth V. (Editor)
Typ dokumentu: Kniha
Jazyk:Angličtina
Vydáno: New York : Kluwer Academic Publishers, [2002]
Edice:Developments in oncology ; 81
Témata:
On-line přístup:Elektronická verze přístupná pouze pro studenty a pracovníky MU
Příbuzné jednotky:Tištěná verze:: Prostate cancer : new horizons in research and treatment
Obsah:
  • Pathology of prostate cancer
  • Prostate cancer susceptibility genes: Many studies, many results, no answers
  • Molecular profiling in prostate cancer
  • Chromosomal deletions and tumor suppressor genes in prostate cancer
  • Role of eicosanoids in prostate cancer progression
  • Contribution of the androgen receptor to prostate cancer predisposition and progression
  • Regulation of apoptosis in prostate cancer
  • On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis
  • Metastasis suppression in prostate cancer
  • The urokinase-type plasminogen activator system in prostate cancer metastasis
  • Angiogenesis in prostate cancer: Biology and therapeutic opportunities
  • Integrins and prostate cancer metastases
  • Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone
  • Signal transduction targets in androgen-independent prostate cancer
  • The diet, prostate inflammation, and the development of prostate cancer
  • Prostate cancer diagnosis, staging and survival
  • Surgery for prostate cancer: Rationale, technique and outcomes
  • The future of cancer imaging
  • Antisense therapy: Current status in prostate cancer and other malignancies
  • Antiangiogenesis therapeutic strategies in prostate cancer
  • Chemoprevention of prostate cancer
  • Prostate brachytherapy
  • Fast neutron irradiation for prostate cancer
  • Prostate cancer gene therapy: Past experiences and future promise
  • Vitamin D-related therapies in prostate cancer
  • Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.